Kuraray Co., Ltd.

Agency of Industrial Science and Technology

Ministry of International Trade & Industry

Yamanouchi Pharmaceutical Company Ltd.

Agency of Industrial Science and Technology Ministry of International

Koichi Takakura

Toshihide Nakashima

Masao Tanihara

Yoshiaki Omura

Hideaki Yamada

Syuji Kawai

Shuzo Yamashita

Kiichiro Oka

Akira Kobayashi

Maso Tanihara

Akio Ohmori

Shiro Nagata

Hirokuni Tanii

Kazuhisa Yamauchi

Takayoshi Suzuki

Osamu Nakaji

A human IgG.sub.1 type monoclonal antibody which possesses a molecular weight in the range of 180,000.+-.20,000 as measured by the method of polyacrylamide gel electrophoresis performed in the presence of sodium dodecyl sulfate and is specific to nicotinic acetylcholine receptor. The human IgG.sub.1 type monoclonal antibody mentioned above is produced by a method which comprises fusing human cells capable of producing an antibody against nicotinic acetylcholine receptor with propagable human cells thereby giving rise to a hybridoma capable of producing the aforementioned human IgG.sub.1 type monoclonal antibody, selecting the hybridoma from the production of the fusion, culturing the hybridoma thereby giving rise to the aforementioned human IgG.sub.1 type monoclonal antibody, and selecting the antibody from the cultured medium. The hybridoma mentioned above is also identified.

Human IgG.sub.1 monoclonal antibody specific for the nicotinic

There is disclosed an adsorbent, comprising a carrier on which is immobilized a peptide possessing an ability to bind to the human antibody to the nicotinic acetylcholine receptor and represented by the formula:

Adsorbent, method for production thereof, and method for use thereof

A monoclonal anti-idiotypic antibody specific to a human IgG.sub.1 type monoclonal antibody possessing specificity to nicotinic acetylcholine receptor; a method for the production of the aforementioned monoclonal anti-idiotypic antibody by the steps of immunizing an animal with a human IgG.sub.1 type monoclonal antibody specific to nicotinic acetylcholine receptor, collecting antibody-producing cells from the animal, fusing the collected cells with neoplastic cells, selecting from the product of fusion a hybridoma capable of producing a monoclonal anti-idiotypic antibody specific to the human IgG.sub.1 type monoclonal antibody possessing specificity to nicotinic acetylcholine receptor, propagating the selected hybridoma thereby giving rise to said monoclonal anti-idiotypic antibody, and collecting the produced monoclonal anti-idiotypic antibody; and use of the monoclonal anti-idiotypic antibody as a reagent and as an adsorbent.

Monoclonal anti-idiotypic antibody, method for production thereof, and

A peptide is disclosed which is represented by the formula:

Peptide

Treatment of the blood by means of a blood purification device comprising packed, substantially spherical, smooth-surfaced, porous granules having at least 0.1 .mu.mole/m.sup.2 of the silanol group on the surface thereof, a blood inlet and a blood outlet scarcely causes decrease in leukocyte or platelet count or blood cell damage and can remove proteins from the blood by adsorption without high pressure loss.

Blood purification method

A column for adsorption of blood proteins is disclosed which comprises a blood inlet and a blood outlet each with a filter, and a porous material packed between both the filters, which material has a mean pore diameter (D) of 30-3,000 amgstroms with the volume occupied by pores with diameters of 0.8D-1.2D being at least 80% of the whole pore volume. The adsorption column can eliminate specific blood proteins by selective adsorption and is useful in the treatment of autoimmune diseases and cancer, for instance.

Column for adsorption of blood proteins

Blood purification device

A column for adsorption of blood proteins is disclosed which comprises a blood inlet and a blood outlet each with a filter, and a porous material packed between both the filters, which material has a mean pore diameter (D) of 30-3,000 angstroms with the volume occupied by pores with diameters of 0.8 D-1.2 D being at least 80% of the whole pore volume. The adsorption column can eliminate specific blood proteins by selective adsorption and is useful in the treatment of autoimmune diseases and cancer, for instance.

Carriers coated with a copolymer of a hydrophilic acrylate or methacrylate monomer and a copolymerizable unsaturated carboxylic acid or unsaturated amine are provided which are substantially free from nonspecific adsorption of proteins and the like. Due to the side-chain carboxyl or amino groups of the copolymer, these coated carriers are able to immobilize bio-active materials such as antigens, antibodies, complements and enzymes. These carriers, on which bio-active materials can be immobilized, are useful as clinical selective adsorbents, affinity-chromatographic adsorbents, selective electrodes or columns for analysis.

Carrier having acrylate copolymer coating for immobilization of

The present invention provides a covering material consisting essentially of a hydrophilic, water insoluble polymer (component A), a high boiling plasticizer and/or organic solvent (component B) for said component A, and an aqueous liquid (component C). Said covering material is useful as a protective covering material for forming a film or coat on the skin and/or wound surface in the treatment of burn. The material is characterized in that film or coat formation on the skin and/or wound surface can be realized in a short time.

Wound covering material

There is described an ethylene-vinyl alcohol copolymer membrane comprising at least a skin layer on its surface and a porous layer supporting the skin layer. The porous layer, when the membrane is observed in the dry state with an electron microscope, contains vacuoles or voids, which present a mono- or multi-layer structure and have straight-line lengths corresponding to 20-99% of the whole thickness of the membrane. In addition, the polymer portion of the porous layer has micropores with an average pore diameter of 0.1-5 microns and the membrane has a porosity of 60-90%.

Ethylene-vinyl alcohol copolymer membrane and a method for producing the

A hemoperfusion adsorbent is provided comprising an adsorbent material containing at least one coating thereon of a hydrophilic polymer prepared by the polymerization of at least one monomeric acrylate or methacrylate with a copolymerizable monomer containing an epoxy moiety therein. In addition, a method is provided for removing air bubbles from such adsorbents comprising boiling said adsorbents in water or physiological saline, cooling said adsorbents, packing said adsorbents into a container and sterilizing the packed container by autoclaving.

Hemoperfusion adsorbents

Ethylene-vinyl alcohol copolymer membranes characterized by constituent particles having an average diameter within the range of from 100 to 10,000 Angstrom units, determined under an electron microscope for the dry membrane, bonded to each other, wherein the membrane is substantially free from pores in excess of from 2 microns in diameter. Such a membrane has a permeability to water of 10 to 200 .times. 10.sup.-16 cm.sup.2 and to vitamin B.sub.12 of not less than 0.8 .times. 10.sup.-7 cm.sup.2 per second, and being of particular value as a membrane for the dialysis of blood. The membrane is obtained by dissolving an ethylenevinyl alcohol copolymer in a solvent consisting essentially of dimethylsulfoxide or dimethylacetamide and causing the resulting solution to coagulate from an aqueous coagulation bath under mild conditions such that the coagulation time as defined in the specification is not less than 3 seconds.

Ethylene-vinyl alcohol copolymer membranes having improved permeability

A polyvinyl alcohol semi-permeable membrane is prepared which has micropores with an average diameter of 0.02 to 2 microns as defined by the interpore partition walls having thicknesses in the range of 50 to 5000 A and which is characterized by substantial cross-sectional uniformity. The membrane is prepared by extruding a PVA composition containing PAG with a molecular weight of 400 to 4,000 and a carbon-to-oxygen ratio of not more than 3 in a proportion of 2 to 200 parts by weight per 100 parts of PVA into a coagulation bath. In another embodiment of the invention, the membrane is formed from a PVA composition wherein the PAG has a molecular weight of 600 to 3,000 and a C/O ratio of not more than 3, the proportion of the PAG being 15 to 150 parts by weight per 100 parts of PVA and wherein the composition satisfies the relation: 0.65 .ltoreq. CBR (critical blending ratio) .ltoreq. 1.0. The membrane is useful in ultrafiltration, dialytic and osmotic separation applications.

Growing community of inventors

Okayama, Japan

Koichi Takakura